Investigators: J. Andrew MacKay, Ph.D. Peter Conti, M.D., Ph.D., Alan Epstein, M.D., Ph.D. Zibo Li, Ph.D.
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients